Dr. Sidney H. Kennedy is Professor of Psychiatry at the University of Toronto, Arthur Sommer Rotenberg Chair in Suicide and Depression Studies at St. Michael’s Hospital, and a Scientist at Li Ka Shing Knowledge Institute and Krembil Research Institute, Toronto, Canada. Dr. Kennedy is the lead investigator for a large depression biomarker initiative, the Canadian Biomarker Integration Network in Depression (CAN-BIND). He is an international leader in Depression Research and Education. Dr. Kennedy's work involves new drug evaluation, neuroimaging and neurostimulation therapies, personality factors in depression, antidepressant effects on sexual function and the development and renewal of treatment guidelines for both Major Depressive Disorder and Bipolar Disorder.
Dr. Kennedy is Immediate Past President of the International Society for Affective Disorders, former President of the Canadian College of Neuropsychopharmacology and Founding Chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT). He is a Distinguished Fellow of the American Psychiatric Association, a fellow of the Canadian Academy of Health Sciences and American College of Neuropsychopharmacology. He is also a member of the European College of Neuropsychopharmacology, and the Collegium Internationale Neuro-Psychopharmacologicum. He is the author of approximately 400 peer reviewed publications and11 books.
Industry Expertise (3)
Areas of Expertise (11)
Queen's University Belfast: MB, BCh, BAO, MD Thesis, Neuroendocrinology
University of Toronto: Diploma, Psychiatry
- International Society for Affective Disorders
- Canadian College of Neuropsychopharmacology
- Canadian Network for Mood and Anxiety Treatments
- Canadian Psychiatric Association
- American Psychiatric Association
- American College of Neuropsychopharmacology
- European College of Neuropsychopharmacology
- International College of Neuropsychopharmacology
Media Appearances (1)
In Session With Sidney H. Kennedy, MD, MBBS, FRCPC
Dr. Sidney Kennedy is a Professor of Psychiatry at the University of Toronto, with extensive experience in treating depression ...
This randomized placebo-controlled "dose relation study" was conducted in patients who met criteria for major depressive disorder, to evaluate the efficacy and safety of agomelatine during 24 weeks at 3 doses (i) low fixed dosage (10mg/day, n=100 patients entered the extension period), (ii) fixed dosage (25mg/day, n=111) and (iii) a flexible dosage with up-titration in case of insufficient improvement at week 2 (25-50mg/day, n=115) versus placebo (n=85). Mood was evaluated using the Hamilton rating scale for depression (HAM-D17) and Clinical Global Impression (CGI) scale.
This study investigated polymorphisms of five inflammatory-related genes for association with duloxetine and placebo response in patients with major depression.
Charts of size at birth are used to assess the postnatal growth of preterm babies on the assumption that extrauterine growth should mimic that in the uterus.
The zebrafish (Danio rerio) has emerged as a model species for translational research in various neuroscience areas, including depressive disorders. Because of their physiological (neuroanatomical, neuroendocrine, neurochemical) and genetic homology to mammals, robust phenotypes, and value in high-throughput genetic and chemical genetic screens, zebrafish are ideal for developing valid experimental models of major depression and discovering novel therapeutics.
Current treatment guidelines emphasize the limited role of benzodiazepines in Major Depressive Disorder (MDD), mainly due to the absence of long-term data, risk of abuse and potential adverse effects. However, benzodiazepines continue to be prescribed for long-term use in a significant number of patients. This study sought to evaluate benzodiazepine use in a large sample of MDD patients seen at a tertiary care clinic, and determine whether use is related to illness severity or complexity, as well as to identify the clinical predictors of benzodiazepine use.